Systematic review links PPARγ to atopic dermatitis pathogenesis and identifies it as a potential therapeutic target

A systematic review synthesized existing mechanistic evidence on the role of peroxisome proliferator-activated receptor gamma (PPARγ) in atopic dermatitis (AD). The review did not report specific study populations, sample sizes, or clinical trial data. It concluded that PPARγ is linked to AD pathogenesis through pleiotropic mechanisms involving epidermal barrier integrity, immune responses, and lipid metabolism, and has emerged as a promising novel therapeutic target.

No clinical results, effect sizes, or comparative efficacy data for PPARγ-targeted interventions were reported. Safety, tolerability, and adverse event profiles for potential therapies are also not reported, as the review focused on preclinical and mechanistic evidence.

Key limitations stem from the review's nature; it synthesizes mechanistic and preclinical findings but does not include primary clinical trial data. The causality note explicitly states the review does not establish causality. The practice relevance acknowledges existing AD treatments have limitations in efficacy and durability, creating an unmet need for novel strategies.

For clinicians, this review highlights a biologically plausible target warranting further investigation. Current evidence remains at the mechanistic level, and no conclusions can be drawn about the clinical utility, safety, or effectiveness of future PPARγ-modulating therapies for AD.